Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency
Status:
Terminated
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of methotrexate in a genetically selected population of patients with
advanced colorectal cancer, who have loss of a particular gene, MSH2. The efficacy of
methotrexate will be evaluated by the proportion of cases that have a significant response to
treatment (objective response rate).